Table 7

Characteristics of DrotAA-treated pediatric patients with PF, MEN, or MD and experienced a serious bleeding event
Characteristic
 During infusion
After infusion
Day of event1
 1
 1
 7
 8
 10
 UD
 UD
Bleeding event






     ICH
 No
 No
 No
 Yes
 No
 Yes
 Yes
     Fatal
 No
 No
 No
 Yes
 No
 Yes
 No
     DrotAA related2
 No
 No
 No
 Yes
 No
 No
 No
Disease category






     PF
 Yes
 Yes
 Yes
 Yes
 Yes
 No
 Yes
     MEN
 No
 Yes
 No
 No
 No
 Yes
 No
     MD
 Yes
 Yes
 Yes
 Yes
 Yes
 Yes
 No
Baseline characteristics






     Protein C level (%)
 36
 -
 16
 41
 -
 34
 -
     Platelet count
 26
 23
 33
 30
 68
 71
 14
     APTT (s)
 68
 165
 121
 220
 73
 111
 -
     PT (s)
 23
 38
 22
 -
 -
 17
 16
     Organ failure
 3
 4
 3
 4
 1
 -
 -

1Day 0 is defined as the calendar day on which DrotAA treatment began; 2This denotes whether or not the investigator considered the bleeding event to be related to treatment with DrotAA. APTT, activated partial thromboplastin time; BL, baseline; DrotAA, drotrecogin alfa (activated); ICH, intracranial hemorrhage; PT, prothrombin time; UD, unknown day after infusion. A dash indicates missing data.

Vincent et al. Critical Care 2005 9:R331   doi:10.1186/cc3538